GUCY2C-targeted cancer immunotherapy: Past, present and future

Immunologic Research

Volumn 51, Issue 2-3, 2011, Pages 161-169

  Snook, Adam E ^a   Magee, Michael S ^a   Waldman, Scott A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Adoptive cell therapy; Cancer; Guanylyl cyclase C; GUCY2C; Immunotherapy

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CYCLOPHOSPHAMIDE; FLUDARABINE; GUANYLATE CYCLASE; GUANYLYL CYCLASE 2C; GUANYLYL CYCLASE C; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LYASE; LYMPHOCYTE ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ADENOVIRUS; ADOPTIVE CELL THERAPY; ADOPTIVE TRANSFER; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PATIENT; COLORECTAL CANCER; CROSS REACTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; HEART ARREST; HUMAN; INTESTINE EPITHELIUM CELL; MELANOMA; META ANALYSIS; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK BENEFIT ANALYSIS; T LYMPHOCYTE; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM;

ADENOCARCINOMA; ADENOVIRIDAE; ANIMALS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; MICE; MOLECULAR TARGETED THERAPY; RECEPTORS, GUANYLATE CYCLASE-COUPLED; RECEPTORS, PEPTIDE;

EID: 84856535080     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-011-8253-7     Document Type: Article

References (101)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA A Cancer J Clin. 2011;61:212-36.
2. Colorectal Cancer. In: Stewart BW, Kleihues P, editors. World cancer report. Lyon: International Agency for Research on Cancer, 2003. pp 198-2.
3. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal Cancer. Lancet. 2005;365:153-65.
4. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
5. Behrens RJ, Achtar M, Herrin V, Gause B, Bernstein S, Brent- Steele T, Maruffi C, Yancey M, Khleif SN: Phase I/II mutant p53 vaccination in advanced malignancies. Proc Am Soc Clin Oncol. 2003;22:186.
6. Carbone DP, Ciernik IF, Kelley MJ, Smith MC, Nadaf S, Kavanaugh D, Maher VE, Stipanov M, Contois D, Johnson BE, Pendleton CD, Seifert B, Carter C, Read EJ, Greenblatt J, Top LE, Kelsey MI, Minna JD, Berzofsky JA: Immunization with mutant p53- and K-ras-derived peptides in cancer patients: Immune response and clinical outcome. J Clin Oncol. 2005;23:5099-7.
7. Ibrahim RA, Achtar MS, Herrin VE, Gause B, Bernstein SA, Brent-Steel TB, Maruffi CM, Berzofsky JA, Khleif SN: Mutant P53 vaccination of patients with advanced cancers generates specific immunological responses. J Clin Oncol ASCO Ann Meet Proc. 2004;22:2521.
8. Moulton HM, Yoshihara PH, Mason DH, Iversen PL, Triozzi PL. Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: Antibody response is associated with improved survival. Clin Cancer Res. 2002;8:2044-51. (Pubitemid 34753572)
9. Kono K, Takahashi A, Sugai H, Fujii H, Choudhury AR, Kiessling R, Matsumoto Y. Dendritic cells pulsed with HER-2/ neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res. 2002;8: 3394-400. (Pubitemid 35340713)
10. Tsuruma T, Hata F, Torigoe T, Furuhata T, Idenoue S, Kurotaki T, Yamamoto M, Yagihashi A, Ohmura T, Yamaguchi K, Katsuramaki T, Yasoshima T, Sasaki K, Mizushima Y, Minamida H, Kimura H, Akiyama M, Hirohashi Y, Asanuma H, Tamura Y, Shimozawa K, Sato N, Hirata K: Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med. 2004;2:19.
11. Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang K-Y, Slack R, Hodge JW, Doren S, Grosenbach DW, Hwang J, Fox E, Odogwu L, Park S, Panicali D, Schlom J: Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol. 2005;23:720-1.
12. Nagao K, Hisatomi H, Hirata H, Yamamoto S, Hikiji K, Yamamoto M, Kanamaru T. Expression of molecular marker genes in various types of normal tissue: Implication for detection of micrometastases. Int J Mol Med. 2002;10:307-10.
13. Bostick PJ, Chatterjee S, Chi DD, Huynh KT, Giuliano AE, Cote R, Hoon DS. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol. 1998;16:2632-40.
14. Pickford WJ, Watson AJ, Barker RN. Different forms of helper tolerance to carcinoembryonic antigen: Ignorance and regulation. Clin Cancer Res. 2007;13:4528-37. (Pubitemid 47219723)
15. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, Restifo NP, Robbins PF, Laurencot CM, Rosenberg SA: T Cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2010.
16. Ahlers JD, Belyakov IM. Lessons learned from natural infection: Focusing on the design of protective T cell vaccines for HIV/AIDS. Trends Immunol. 2010;31:120-30.
17. Belyakov IM, Ahlers JD. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J Immunol. 2009;183:6883-92.
18. Qimron U, Paul L, Bar-Haim E, Bloushtain N, Eisenbach L, Staats HF, Porgador A. Non-replicating mucosal and systemic vaccines: Quantitative and qualitative differences in the Ag-specific CD8(?) T cell population in different tissues. Vaccine. 2004;22:1390-4. (Pubitemid 38446915)
19. Hamann A, Andrew DP, Jablonski-Westrich D, Holzmann B, Butcher EC. Role of alpha 4-integrins in lymphocyte homing to mucosal tissues in vivo. J Immunol. 1994;152:3282-93.
20. Berlin C, Berg EL, Briskin MJ, Andrew DP, Kilshaw PJ, Holzmann B, Weissman IL, Hamann A, Butcher EC. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell. 1993;74:185-95.
21. Campbell DJ, Butcher EC. Rapid acquisition of tissue-specific homing phenotypes by CD4+ T cells activated in cutaneous or mucosal lymphoid tissues. J Exp Med. 2002;195:135-41. (Pubitemid 34074503)
22. Mowat AM, Viney JL. The anatomical basis of intestinal immunity. Immunol Rev. 1997;156:145-66. (Pubitemid 27197200)
23. Garside P, Millington O, Smith KM. The anatomy of mucosal immune responses. Ann N Y Acad Sci. 2004;1029:9-15. (Pubitemid 40298510)
24. Cromwell MA, Veazey RS, Altman JD, Mansfield KG, Glickman R, Allen TM, Watkins DI, Lackner AA, Johnson RP. Induction of mucosal homing virus-specific CD8+ T lymphocytes by attenuated simian immunodeficiency virus. J Virol. 2000;74:8762-6. (Pubitemid 30666728)
25. Belyakov IM, Wyatt LS, Ahlers JD, Earl P, Pendleton CD, Kelsall BL, Strober W, Moss B, Berzofsky JA. Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein. J Virol. 1998;72:8264-72. (Pubitemid 28421824)
26. Belyakov IM, Moss B, Strober W, Berzofsky JA. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc Natl Acad Sci USA. 1999;96:4512-7. (Pubitemid 29190367)
27. Belyakov IM, Ahlers JD, Brandwein BY, Earl P, Kelsall BL, Moss B, Strober W, Berzofsky JA. The importance of local mucosal HIV-specific CD8+ cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. J Clin Invest. 1998;102:2072-81. (Pubitemid 29018813)
28. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, Waldman SA. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev. 2000;52:375-414.
29. Li P, Lin JE, Chervoneva I, Schulz S, Waldman SA, Pitari GM. Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine. Am J Pathol. 2007;171:1847-58.
30. Lin JE, Li P, Snook AE, Schulz S, Dasgupta A, Hyslop TM, Gibbons AV, Marszlowicz G, Pitari GM, Waldman SA. The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling. Gastroenterology. 2009;138: 241-54.
31. Schulz S, Green CK, Yuen PS, Garbers DL. Guanylyl cyclase is a heat-stable enterotoxin receptor. Cell. 1990;63:941-8. (Pubitemid 120034935)
32. Krause WJ, Cullingford GL, Freeman RH, Eber SL, Richardson KC, Fok KF, Currie MG, Forte LR. Distribution of heat-stable enterotoxin/guanylin receptors in the intestinal tract of man and other mammals. J Anat. 1994;184(Pt 2):407-17. (Pubitemid 24114601)
33. Nandi A, Bhandari R, Visweswariah SS. Epitope conservation and immunohistochemical localization of the guanylin/stable toxin peptide receptor, guanylyl cyclase C. J Cell Biochem. 1997;66:500-11. (Pubitemid 27377615)
34. Li Z, Perkins AG, Peters MF, Campa MJ, Goy MF. Purification, cDNA sequence, and tissue distribution of rat uroguanylin. Regul Pept. 1997;68:45-56. (Pubitemid 27117802)
35. Almenoff JS, Williams SI, Scheving LA, Judd AK, Schoolnik GK. Ligand-based histochemical localization and capture of cells expressing heat-stable enterotoxin receptors. Mol Microbiol. 1993;8:865-73. (Pubitemid 23171468)
36. Swenson ES, Mann EA, Jump ML, Witte DP, Giannella RA. The guanylin/STa receptor is expressed in crypts and apical epithelium throughout the mouse intestine. Biochem Biophys Res Commun. 1996;225:1009-14. (Pubitemid 26319218)
37. Qian X, Prabhakar S, Nandi A, Visweswariah SS, Goy MF. Expression of GC-C, a receptor-guanylate cyclase, and its endogenous ligands uroguanylin and guanylin along the rostrocaudal axis of the intestine. Endocrinology. 2000;141:3210-24. (Pubitemid 32269009)
38. Birbe R, Palazzo JP, Walters R, Weinberg D, Schulz S, Waldman SA. Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum Pathol. 2005;36:170-9. (Pubitemid 40313574)
39. Carrithers SL, Parkinson SJ, Goldstein SD, Park PK, Urbanski RW, Waldman SA. Escherichia coli heat-stable enterotoxin receptors. A novel marker for colorectal tumors. Dis Colon Rectum. 1996;39:171-81.
40. Carrithers SL, Barber MT, Biswas S, Parkinson SJ, Park PK, Goldstein SD, Waldman SA. Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proc Natl Acad Sci USA. 1996;93:14827-32. (Pubitemid 26419054)
41. Guarino A, Cohen MB, Overmann G, Thompson MR, Giannella RA. Binding of E. coli heat-stable enterotoxin to rat intestinal brush borders and to basolateral membranes. Dig Dis Sci. 1987;32:1017-26. (Pubitemid 17137984)
42. Li Z, Goy MF. Peptide-regulated guanylate cyclase pathways in rat colon: In situ localization of GCA, GCC, and guanylin mRNA. Am J Physiol. 1993;265:G394-402. (Pubitemid 23273646)
43. Krause G, Bayerl A, Heim JM, Singh S, Gerzer R. Distribution of membrane bound guanylyl cyclases in human intestine. Gut. 1994;35:1250-7. (Pubitemid 24277339)
44. Cagir B, Gelmann A, Park J, Fava T, Tankelevitch A, Bittner EW, Weaver EJ, Palazzo JP, Weinberg D, Fry RD, Waldman SA. Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer. Ann Intern Med. 1999;131:805-12.
45. Waldman SA, Cagir B, Rakinic J, Fry RD, Goldstein SD, Isenberg G, Barber M, Biswas S, Minimo C, Palazzo J, Park PK, Weinberg D. Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer. Dis Colon Rectum. 1998;41:310-5. (Pubitemid 28141595)
46. Waldman SA, Hyslop T, Schulz S, Barkun A, Nielsen K, Haaf J, Bonaccorso C, Li Y, Weinberg DS. Association of GUCY2C expression in lymph nodes with time to recurrence and diseasefree survival in pN0 colorectal cancer. JAMA. 2009;301: 745-52.
47. Wilson JM, Engelhardt JF, Grossman M, Simon RH, Yang Y. Gene therapy of cystic fibrosis lung disease using E1 deleted adenoviruses: A phase I trial. Hum Gene Ther. 1994;5:501-19.
48. Senior K: Gene therapy: A rocky start to the new millennium. Mol Med Today. 2000;6:93. (Pubitemid 30148512)
49. Liniger M, Zuniga A, Naim HY. Use of viral vectors for the development of vaccines. Expert Rev Vaccin. 2007;6:255-66. (Pubitemid 46613525)
50. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1977;36:59-74.
51. Kozarsky KF, Wilson JM. Gene therapy: Adenovirus vectors. Curr Opin Genet Dev. 1993;3:499-503. (Pubitemid 23220755)
52. Krougliak V, Graham FL. Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. Hum Gene Ther. 1995;6:1575-86. (Pubitemid 26014568)
53. Yoo GH, Moon J, Leblanc M, Lonardo F, Urba S, Kim H, Hanna E, Tsue T, Valentino J, Ensley J, Wolf G: A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: Report of the Southwest Oncology Group. Arch Otolaryngol Head Neck Surg. 2009;135:869-4.
54. Zhang S, Li Y, Li L, Zhang Y, Gao N, Zhang Z, Zhao H. Phase I study of repeated intraepithelial delivery of adenoviral p53 in patients with dysplastic oral leukoplakia. J Oral Maxillofac Surg. 2009;67:1074-82.
55. Xu F, Li S, Li XL, Guo Y, Zou BY, Xu R, Liao H, Zhao HY, Zhang Y, Guan ZZ, Zhang L. Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors. Cancer Gene Ther. 2009;16:723-30.
56. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S, Marmor M, Lally M, Novak RM, Brown SJ, Kulkarni P, Dubey SA, Kierstead LS, Casimiro DR, Mogg R, DiNubile MJ, Shiver JW, Leavitt RY, Robertson MN, Mehrotra DV, Quirk E. Safety and immunogenicity of a replicationincompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis. 2008;46:1769-81. (Pubitemid 351706778)
57. Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Gu L, Martin JE, Novik L, Chakrabarti BK, Butman BT, Gall JG, King CR, Andrews CA, Sheets R, Gomez PL, Mascola JR, Nabel GJ, Graham BS. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis. 2006;194:1638-49. (Pubitemid 44901994)
58. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372:1881-93.
59. Snook AE, Stafford BJ, Li P, Tan G, Huang L, Birbe R, Schulz S, Schnell MJ, Thakur M, Rothstein JL, Eisenlohr LC, Waldman SA. Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity. J Natl Cancer Inst. 2008;100:950-61. (Pubitemid 351957514)
60. Snook AE, Li P, Stafford BJ, Faul EJ, Huang L, Birbe RC, Bombonati A, Schulz S, Schnell MJ, Eisenlohr LC, Waldman SA. Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease. Cancer Res. 2009;69:3537-44.
61. Snook AE, Huang L, Schulz S, Eisenlohr LC, Waldman SA. Cytokine adjuvanation of therapeutic anti-tumor immunity targeted to cancer mucosa antigens. Clin Trans Sci. 2008;1:263-4.
62. Nagorsen D, Thiel E. Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res. 2006;12:3064-9. (Pubitemid 43837352)
63. Draft Guidance: Clinical considerations for therapeutic cancer vaccines 2009.
64. Mosolits S, Nilsson B, Mellstedt H. Towards therapeutic vaccines for colorectal carcinoma: A review of clinical trials. Expert Rev Vaccines. 2005;4:329-50. (Pubitemid 40978696)
65. Mosolits S, Ullenhag G, Mellstedt H. Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Ann Oncol. 2005;16: 847-62.
66. Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin. 2004;54:295-308. (Pubitemid 40073988)
67. Greene FL. AJCC cancer staging manual. New York: Springer; 2002.
68. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: Moving beyond current vaccines. Nat Med. 2004;10:909-15. (Pubitemid 39273730)
69. Rosenberg SA: Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat Rev Clin Oncol 2011.
70. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21:233-40.
71. Morgan RA, Dudley ME, Rosenberg SA. Adoptive cell therapy: Genetic modification to redirect effector cell specificity. Cancer J. 2010;16:336-41.
72. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA. Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA. 1995;92:11993-7. (Pubitemid 26013997)
73. Parkhurst MR, Joo J, Riley JP, Yu Z, Li Y, Robbins PF, Rosenberg SA. Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin Cancer Res. 2009;15:169-80.
74. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol. 2006;90:51-81. (Pubitemid 43765799)
75. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA. 1993;90:720-4. (Pubitemid 23028937)
76. Bridgeman JS, Hawkins RE, Hombach AA, Abken H, Gilham DE. Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther. 2010;10:77-90.
77. Guest RD, Hawkins RE, Kirillova N, Cheadle EJ, Arnold J, O'Neill A, Irlam J, Chester KA, Kemshead JT, Shaw DM, Embleton MJ, Stern PL, Gilham DE. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: Evaluation of four different scFvs and antigens. J Immunother. 2005;28:203-11. (Pubitemid 40593985)
78. Wilkie S, Picco G, Foster J, Davies DM, Julien S, Cooper L, Arif S, Mather SJ, Taylor-Papadimitriou J, Burchell JM, Maher J. Retargeting of human T cells to tumor-associated MUC1: The evolution of a chimeric antigen receptor. J Immunol. 2008;180: 4901-9.
79. Emtage PC, Lo AS, Gomes EM, Liu DL, Gonzalo-Daganzo RM, Junghans RP. Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: A preclinical evaluation. Clin Cancer Res. 2008;14:8112-22.
80. Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors: Costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol. 2004;172:104-13. (Pubitemid 38020461)
81. Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA: Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood. 2010.
82. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler- Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, Morgan RA, Rosenberg SA: Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically-engineered to recognize CD19. Blood. 2010.
83. Song D, Ye Q, Carpenito C, Poussin M, Wang LP, Ji C, Figini M, June CH, Coukos G, Sr., Powell DJ, Jr.: Improved T cell survival provided by CD137 costimulatory signaling to folate receptor- redirected T cells results in tumor localization and eradication. Cancer Res. 2011.
84. Porter DL, Levine BL, Kalos M, Bagg A, June CH: Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011.
85. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, Varela-Rohena A, Haines KM, Heitjan DF, Albelda SM, Carroll RG, Riley JL, Pastan I, June CH. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA. 2009;106:3360-5.
86. Pule MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005;12:933-41. (Pubitemid 41614489)
87. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Dotti G: CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011.
88. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH: T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3:95ra73.
89. Porter DL, Kalos M, Zheng Z, Levine B, June C. Chimeric antigen receptor therapy for B-cell malignancies. J Cancer. 2011;2:331-2.
90. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-4. (Pubitemid 35231542)
91. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, Gratama JW, Stoter G, Oosterwijk E. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience. J Clin Oncol. 2006;24:e20-2.
92. Bos R, van Duikeren S, Morreau H, Franken K, Schumacher TN, Haanen JB, van der Burg SH, Melief CJ, Offringa R. Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res. 2008;68:8446-55.
93. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843-51.
94. Ertl HC, Zaia J, Rosenberg SA, June CH, Dotti G, Kahn J, Cooper LJ, Corrigan-Curay J, Strome SE. Considerations for the clinical application of chimeric antigen receptor T cells: Observations from a recombinant DNA advisory committee symposium held, June 15, 2010. Cancer Res. 2011;71:3175-81.
95. Jensen MC, Popplewell L, Cooper LJ, Digiusto D, Kalos M, Ostberg JR, Forman SJ: Anti-transgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor re-directed T cells in humans. Biol Blood Marrow Transplant. 2010.
96. Quintarelli C, Vera JF, Savoldo B, Giordano Attianese GM, Pule M, Foster AE, Heslop HE, Rooney CM, Brenner MK, Dotti G. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007;110:2793-802. (Pubitemid 350006931)
97. Snook AE, Eisenlohr LC, Rothstein JL, Waldman SA. Cancer mucosa antigens as a novel immunotherapeutic class of tumorassociated antigen. Clin Pharmacol Ther. 2007;82:734-9. (Pubitemid 350114818)
98. Kulaksiz H, Rehberg E, Stremmel W, Cetin Y. Guanylin and functional coupling proteins in the human salivary glands and gland tumors: Expression, cellular localization, and target membrane domains. Am J Pathol. 2002;161:655-64. (Pubitemid 36142174)
99. Valentino MA, Lin JE, Snook AE, Li P, Kim GW, Marszalowicz G, Magee MS, Hyslop T, Schulz S, Waldman SA: A uroguanylin-GUCY2C endocrine axis regulates feeding in mice. J Clin Invest. 2011.
100. Zhang L, Kerkar SP, Yu Z, Zheng Z, Yang S, Restifo NP, Rosenberg SA, Morgan RA. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther. 2011;19:751-9.
101. Chmielewski M, Kopecky C, Hombach A, Abken H: IL-12 release by macrophages expressing chimeric antigen receptors can effectively restore T cell attacks on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011.